Overexpression of granulocyte colony-stimulating factor induces severe osteopenia in developing mice that is partially prevented by a diet containing vitamin K2 (menatetrenone).
Mice transgenic for granulocyte colony-stimulating factor (G-CSF) exhibit severe osteopenia with an increase of osteoclast number and acceleration of bone resorption in adult mice. To examine the effect of G-CSF overexpression on developing bone, bone mineral density levels were examined from 4 weeks through 36 weeks after birth. Peak bone mass was observed at around 24 weeks of age irrespective of G-CSF expression. Apparent osteopenia was observed as early as 4 weeks of age without detectable developmental retardation in bone length and skeletal structure. Morphological examination confirmed a reduction of cancellous bone and cortical bone at this early stage of life, indicating that overexpression of G-CSF results in apparent osteopenia in developing mice, similar to that in adult animals. The effect of vitamin K2 (menatetrenone) (MK4) on bone phenotypes during development was then examined. Mice were fed chow containing either 0.05 mg MK-4 per 100 g or 20.0 mg MK-4 per 100 g for 12 weeks as the control and experimental diets, respectively. This treatment did not change bone length, irrespective of the type of mouse or diet. Peripheral quantitative computed tomography (pQCT) revealed an increase of in CT value bone of MK4-treated mice. Taken together, these results indicate that overexpression of G-CSF induces an apparent reduction of bone mass and results in osteopenia in developing mice. The bone reduction was partially restored by feeding the mice MK4, suggesting a choice for treatment on the osteopenia induced by G-CSF.
Kokai
Y
Y
Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan. yasokoki@sapmed.ac.jp
Wada
T
T
Oda
T
T
Kuwabara
H
H
Hara
K
K
Akiyama
Y
Y
Ishii
S
S
Sawada
N
N
D000818:Animals; D001851:Bone Diseases, Metabolic / Q000178:diet therapy* / Q000378:metabolism* / Q000473:pathology / Q000517:prevention & control; D001842:Bone and Bones / Q000378:metabolism / Q000473:pathology; D016179:Granulocyte Colony-Stimulating Factor / Q000096:biosynthesis*; D051379:Mice; D008822:Mice, Transgenic; D024482:Vitamin K 2 / Q000031:analogs & derivatives* / Q000627:therapeutic use*
D024482:Vitamin K 2; D016179:Granulocyte Colony-Stimulating Factor; C030814:menatetrenone